Literature DB >> 15356648

PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells.

S Lentzsch1, M Chatterjee, M Gries, K Bommert, H Gollasch, B Dörken, R C Bargou.   

Abstract

IL-6 has been reported to play a central role in growth and survival of multiple myeloma (MM) cells. However, recently we have demonstrated that in the presence of bone marrow stromal cells, survival of MM cells becomes independent of the IL-6/gp130/STAT3 pathway questioning the singular role of IL-6 in MM. Therefore, it was the aim of this study to identify additional factors and signaling pathways that might contribute to the growth and survival of MM cells. We found that in addition to IL-6 a number of bone marrow derived cytokines such as LIF, VEGF, bFGF, MIP-1alpha, SDF-1alpha, IL-1beta, SCF and IL-3 activate the MAPK pathway and induce proliferation of MM.1S and RPMI-8226 MM cells. In addition, these cytokines independently phosphorylate the forkhead family member FKHR via PI3-K/AKT and support survival of primary human MM cells. Inhibition of these pathways induces apoptosis in MM cell lines and primary MM cells. Thus, we provide evidence that in addition to IL-6 a number of different factors trigger important growth-promoting pathways to support the proliferation and survival of MM cells. Therefore, blocking such pathways, rather than blocking a single factor, might be a promising approach for the development of novel treatment strategies in MM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356648     DOI: 10.1038/sj.leu.2403486

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  31 in total

1.  Naltrindole inhibits human multiple myeloma cell proliferation in vitro and in a murine xenograft model in vivo.

Authors:  Jyoti Joshi Mundra; Alexandra Terskiy; Richard D Howells
Journal:  J Pharmacol Exp Ther       Date:  2012-04-26       Impact factor: 4.030

2.  Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

Authors:  Teru Hideshima; Laurence Catley; Hiroshi Yasui; Kenji Ishitsuka; Noopur Raje; Constantine Mitsiades; Klaus Podar; Nikhil C Munshi; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

3.  Role of dephosphorylation of FOXO1 on apoptosis induced by wortmannin for non-Hodgkin's lymphoma cells.

Authors:  Zhan Qiong; Huang Ruofan; Liang Xiaohua; Zhou Xinli; Jiang Jingwei; Chu Zhaohui
Journal:  Mol Biol Rep       Date:  2009-09-11       Impact factor: 2.316

Review 4.  Signaling Pathways and Emerging Therapies in Multiple Myeloma.

Authors:  Vijay Ramakrishnan; Anita D'Souza
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

5.  Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone.

Authors:  Timothy N Trotter; Justin T Gibson; Tshering Lama Sherpa; Pramod S Gowda; Deniz Peker; Yang Yang
Journal:  Am J Pathol       Date:  2016-09-17       Impact factor: 4.307

6.  Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis.

Authors:  Ming Ruan; Larry Pederson; Elizabeth W Bradley; Ana-Maria Bamberger; Merry Jo Oursler
Journal:  Endocrinology       Date:  2010-02-24       Impact factor: 4.736

7.  Human umbilical cord blood cells protect oligodendrocytes from brain ischemia through Akt signal transduction.

Authors:  Derrick D Rowe; Christopher C Leonardo; Jesus A Recio; Lisa A Collier; Alison E Willing; Keith R Pennypacker
Journal:  J Biol Chem       Date:  2011-12-12       Impact factor: 5.157

8.  Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth.

Authors:  Renate Burger; Andreas Günther; Katja Klausz; Matthias Staudinger; Matthias Peipp; Eva Maria Murga Penas; Stefan Rose-John; John Wijdenes; Martin Gramatzki
Journal:  Haematologica       Date:  2016-09-22       Impact factor: 9.941

9.  Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells.

Authors:  Tuoen Liu; Zhiqiang Fei; Kalyan J Gangavarapu; Senyo Agbenowu; Alok Bhushan; James C K Lai; Christopher K Daniels; Shousong Cao
Journal:  Leuk Res       Date:  2013-07-18       Impact factor: 3.156

10.  Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.

Authors:  J S Waizenegger; I Ben-Batalla; N Weinhold; T Meissner; M Wroblewski; M Janning; K Riecken; M Binder; D Atanackovic; H Taipaleenmaeki; D Schewe; S Sawall; V Gensch; M Cubas-Cordova; A Seckinger; W Fiedler; E Hesse; N Kröger; B Fehse; D Hose; B Klein; M S Raab; K Pantel; C Bokemeyer; S Loges
Journal:  Leukemia       Date:  2014-08-08       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.